Biotechnology

Navidea Biopharm

Navidea Biopharmaceutical Extends Rights Agreement to 2027

Navidea Biopharm released FY2020 Q3 earnings on November 12 After-Market EST, with actual revenue of 268,389 USD and EPS of -0.1278

Lavoro

Sky Quarry

Brand Engagement Network

Datavault AI

Netclass Tech

Atlantic

AgEagle Aerial

Polyrizon

Hyperscale Data

TRAILBLAZER MERGER CORP I USD0.0001 CL A (S/R21/04/2028)

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Navidea Biopharm(NAVB.US)